A Multicenter Phase 2 Trial to Evaluate Intracranial Response to Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Who Are Anti-PD1/PD-L1 Experienced
Kidney | Melanoma, skin
What is the purpose of this trial?
This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).
- Trial withYale Cancer Center
- Start Date02/08/2022
- End Date06/01/2025
- Last Updated12/22/2022
- Study HIC#2000030391